Discontinuation report APO-LAMIVUDINE HBV
| Report ID | 60563 |
| Drug Identification Number | 02393239 |
| Brand name | APO-LAMIVUDINE HBV |
| Common or Proper name | LAMIVUDINE |
| Company Name | APOTEX INC |
| Market Status | MARKETED |
| Active Ingredient(s) | LAMIVUDINE |
| Strength(s) | 100MG |
| Dosage form(s) | TABLET |
| Route of administration | ORAL |
| Packaging size | 60 BTL |
| ATC code | J05AF |
| ATC description | DIRECT ACTING ANTIVIRALS |
| Reason for discontinuation | Business reasons |
| Anticipated discontinuation date | 2019-07-04 |
| Actual discontinuation date | 2019-12-20 |
| Remaining supply date | 2019-12-20 |
| Discontinuation status | Discontinued |
| Discontinuation decision reversal | No |
| Information on remaining supply | |
| Company comments | |
| Health Canada comments | |
| Tier 3 Status | No |
| Contact Address | 150 SIGNET DRIVE TORONTO, ONTARIO CANADA M9L 1T9 |
| Company contact information | Apotex Customer Service - 1-877-427-6839 |
Version History
Click on "Compare" below to view the full report history and compare to other versions.
| Version Number | Date Updated | Language | |
|---|---|---|---|
| v5 | 2019-12-21 | English | Compare |
| v4 | 2019-12-20 | French | Compare |
| v3 | 2019-12-20 | English | Compare |
| v2 | 2018-09-07 | French | Compare |
| v1 | 2018-09-07 | English | Compare |
Showing 1 to 5 of 5